GlaxoSmithKline Pharmaceuticals Current Share Price | GlaxoSmithKline Pharmaceuticals Stock Screener
GLAXO
Pharmaceuticals
GlaxoSmithKline Pharmaceuticals Current Stock Price Today
Live Share Price NSE
₹2838.80
▲
38.90 (1.39%)
Live Share Price BSE
₹2851.85
▲
51.40 (1.84%)
As of September 18, 2026, the live GlaxoSmithKline Pharmaceuticals share price (NSE: GLAXO) is ₹2,838.80 on NSE and ₹2,851.85 on BSE, up 1.39% from the previous close, with shares trading between ₹2,800.00 and ₹2,900.00 in today's trading session, and a 52-week range of ₹2,103.20–₹3,106.40.
Browse GlaxoSmithKline Pharmaceutical annual reports to support your investment research.
Use the GlaxoSmithKline Pharmaceuticals stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
GlaxoSmithKline Pharmaceuticals Market Cap
₹48,385.75 Cr.
GLAXO P/E Ratio (TTM)
44.63
GlaxoSmithKline Pharmaceuticals P/B Ratio
21.03
EPS (TTM)
₹61.15
Dividend Yield
2.03%
Debt to Equity
0.01
GLAXO 52 Week High
₹3106.40
GlaxoSmithKline Pharmaceuticals 52 Week Low
₹2103.20
Operating Margin
31.00%
Profit Margin
24.13%
GLAXO Revenue (TTM)
₹982.00
EBITDA
₹339.00
Net Income
₹237.00
Total Assets
₹4,324.00
Total Equity
₹2,267.00
GlaxoSmithKline Pharmaceuticals Current Share Price Chart
Track the current GlaxoSmithKline Pharmaceuticals share price and stock price with an interactive chart. Analyse GLAXO price trends, trading volume, historical performance, and volatility across different timeframes — the complete GlaxoSmithKline Pharmaceuticals stock quote in one place.
GlaxoSmithKline Pharmaceuticals Company Profile - Fundamental Screener
Screen GlaxoSmithKline Pharmaceuticals company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for GLAXO shares.
GlaxoSmithKline Pharmaceuticals Limited is an Indian subsidiary of UK-based GSK Plc, engaged in manufacturing, distributing, and trading pharmaceuticals. The company operates in three main product areas: vaccines, specialty medicines, and general medicines. It has manufacturing facilities in Nashik and Thane, with a clinical development center in Bangalore. The company's portfolio...more
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
Chairperson/CEO
Renu S. Karnad
ISIN
INE159A01016
Website
https://www.gsk-india.com
GlaxoSmithKline Pharmaceuticals Balance Sheet Screener
Screen GLAXO balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 4,324 | 4,108 | 3,557 | 3,327 | 4,633 | 3,115 | 3,136 | 3,911 | 3,948 | 3,004 |
| Current Assets | 3,606 | 3,410 | 2,798 | 2,494 | 3,708 | 2,203 | 1,775 | 2,010 | 2,186 | 1,674 |
| Fixed Assets | 281 | 284 | 321 | 330 | 331 | 387 | 758 | 432 | 325 | 258 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 277 | 252 | 254 | 259 | 272 | 282 | 291 | 317 | 290 | 277 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 2,267 | 1,951 | 1,778 | 1,741 | 2,663 | 1,478 | 1,821 | 2,140 | 2,057 | 2,007 |
| Share Capital | 169 | 169 | 169 | 169 | 169 | 169 | 169 | 169 | 85 | 85 |
| Reserves & Surplus | 2,098 | 1,782 | 1,608 | 1,572 | 2,494 | 1,309 | 1,651 | 1,970 | 1,973 | 1,922 |
GlaxoSmithKline Pharmaceuticals Income Statement Screener - Profit & Revenue Analysis
Screen GlaxoSmithKline Pharmaceuticals income statement and profit fundamentals.
Analyze GLAXO quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for GlaxoSmithKline Pharmaceuticals share price evaluation.
| Item | 2026-Jun | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar | 2022-Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 982 | 1,031 | 1,091 | 1,016 | 849 | 1,015 | 985 | 1,050 | 850 | 962 | 833 | 985 | 815 | 826 | 826 |
| Expenses | 643 | 644 | 670 | 644 | 554 | 641 | 658 | 689 | 584 | 673 | 751 | 668 | 618 | 618 | 585 |
| EBITDA | 339 | 387 | 421 | 372 | 295 | 374 | 327 | 361 | 266 | 290 | 83 | 318 | 198 | 208 | 241 |
| Operating Profit % | 31.00% | 35.00% | 36.00% | 34.00% | 31.00% | 34.00% | 31.00% | 32.00% | 28.00% | 28.00% | 7.00% | 30.00% | 19.00% | 22.00% | 27.00% |
| Depreciation | 16 | 13 | 20 | 17 | 16 | 15 | 19 | 17 | 16 | 18 | 17 | 18 | 16 | 17 | 16 |
| Interest | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 |
| Profit Before Tax | 323 | 373 | 400 | 354 | 279 | 359 | 308 | 344 | 249 | 271 | 65 | 299 | 181 | 190 | 224 |
| Tax | 85 | 95 | 104 | 97 | 74 | 96 | 78 | 91 | 67 | 76 | 20 | 82 | 49 | 57 | 60 |
| Net Profit | 237 | 278 | 296 | 258 | 205 | 263 | 230 | 253 | 182 | 195 | 46 | 218 | 132 | 133 | 165 |
| EPS | 14.00 | 16.40 | 16.54 | 15.07 | 12.10 | 15.52 | 13.57 | 14.67 | 10.76 | 11.37 | 9.89 | 12.84 | 7.04 | 7.41 | 9.71 |
GlaxoSmithKline Pharmaceuticals Cash Flow Screener - Liquidity Fundamentals
Screen GLAXO cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 903 | 1,290 | 582 | 484 | 811 | 578 | 491 | 410 | 473 | 234 |
| Investing Activities | 397 | -46 | 9 | 808 | -406 | 418 | -57 | -153 | -104 | 301 |
| Financing Activities | -737 | -769 | -562 | -1,543 | -524 | -696 | -428 | -358 | -307 | -511 |
| Net Cash Flow | 563 | 475 | 29 | -251 | -119 | 300 | 6 | -102 | 62 | 24 |
GlaxoSmithKline Pharmaceuticals Shareholding Pattern Screener
See GlaxoSmithKline Pharmaceuticals shareholding pattern with promoter, FII, and DII holdings.
Check GlaxoSmithKline Pharmaceuticals promoter holding and ownership changes for GLAXO on TickJournal.
| Item | 2026-Mar | 2026-Jun | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% |
| FII Holding | 4.62% | 4.79% | 4.52% | 4.89% | 4.80% | 4.64% | 3.48% | 4.02% |
| DII Holding | 7.68% | 7.80% | 7.79% | 7.70% | 7.75% | 7.70% | 7.90% | 7.50% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 10.35% | 10.21% | 10.60% | 10.32% | 10.34% | 10.36% | 11.27% | 11.15% |
| Other Holding | 2.35% | 2.20% | 2.09% | 2.09% | 2.11% | 2.30% | 2.35% | 2.33% |
| Shareholder Count | 121,763 | 126,087 | 121,885 | 123,629 | 122,904 | 122,460 | 118,994 | 118,515 |
GlaxoSmithKline Pharmaceuticals Share Dividend Screener - Share Yield Analysis
Check GlaxoSmithKline Pharmaceuticals dividend history with payout and yield data.
View GlaxoSmithKline Pharmaceuticals dividend details including ex-dates and amounts for GLAXO stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹57.00 | 2.02% |
| 2025-March | ₹54.00 | 2.37% |
| 2024-March | ₹32.00 | 1.11% |
| 2023-March | ₹32.00 | 1.64% |
| 2022-March | ₹90.00 | 7.05% |
| 2021-March | ₹30.00 | 1.80% |
| 2020-March | ₹40.00 | 2.78% |
| 2019-March | ₹20.00 | 1.59% |
| 2018-March | ₹35.00 | 2.70% |
| 2017-March | ₹30.00 | 2.87% |
GlaxoSmithKline Pharmaceuticals Stock Index Membership
See which indices include GlaxoSmithKline Pharmaceuticals stock.
Check GLAXO index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
BSE 1000
BSE 200 EQUAL WEIGHT
BSE INDEX BSE HC
BSE INDEX BSE200
BSE INDEX BSE500
BSE INDEX BSEQUI
BSE INDEX LMI250
BSE INDEX MID150
BSE INDEX MIDCAP
BSE INDEX MSL400
NIFTY 500
NIFTY LARGEMID250
NIFTY M150 QLTY50
NIFTY MIDCAP 150
NIFTY MIDSML 400
NIFTY MIDSML HLTH
NIFTY TOTAL MKT
NIFTY500 EQUAL WEIGHT
NIFTY500 LARGEMIDSMALL EQUAL CAP WEIGHTED
NIFTY500 MULTICAP
GlaxoSmithKline Pharmaceuticals Market Events Screener - Corporate Actions
Get GlaxoSmithKline Pharmaceuticals corporate actions including splits, bonuses, and buybacks.
Check GlaxoSmithKline Pharmaceuticals stock events that may affect GLAXO share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-08-03 | 2026-08-03 | Quarterly Result Announcement | NA | 6.86% |
| 2026-06-30 | 2026-06-30 | Annual General Meeting | NA | -3.82% |
| 2026-05-29 | 2026-05-29 | Dividend | ₹ 57.00 /share | -6.20% |
| 2026-05-13 | 2026-05-13 | Quarterly Result Announcement | NA | 0.87% |
| 2026-02-09 | 2026-02-09 | Quarterly Result Announcement | NA | 1.10% |
| 2025-11-06 | 2025-11-06 | Quarterly Result Announcement | NA | -3.50% |
| 2025-08-01 | 2025-08-01 | Quarterly Result Announcement | NA | -3.21% |
| 2025-06-27 | 2025-06-27 | Annual General Meeting | NA | 21.34% |
| 2025-05-30 | 2025-05-30 | Dividend | ₹ 42.00 /share | 19.92% |
| 2025-05-13 | 2025-05-13 | Quarterly Result Announcement | NA | -7.08% |
| 2025-02-14 | 2025-02-14 | Quarterly Result Announcement | NA | -3.77% |
| 2024-11-07 | 2024-11-07 | Dividend | ₹ 12.00 /share | -0.47% |
| 2024-10-29 | 2024-10-29 | Quarterly Result Announcement | NA | 0.52% |
| 2024-06-28 | 2024-06-28 | Annual General Meeting | NA | 32.30% |
| 2024-05-31 | 2024-05-31 | Dividend | ₹ 32.00 /share | 28.12% |
GlaxoSmithKline Pharmaceuticals Competitors Screener - Peer Comparison
Screen GLAXO competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 444,717 | 36.34 | 61,674 | 12.69% | 11,565 | 38.94 |
| Divis Laboratories | 243,116 | 83.41 | 11,067 | 13.95% | 2,568 | 57.81 |
| Torrent Pharmaceuticals | 183,052 | 85.57 | 13,886 | 20.34% | 2,138 | 42.03 |
| Zydus Life Science | 111,440 | 23.87 | 27,658 | 17.64% | 5,026 | 43.86 |
| Cipla | 109,705 | 32.76 | 29,045 | 2.24% | 3,870 | 35.04 |
| Laurus Labs | 102,870 | 95.29 | 6,868 | 22.01% | 890 | 56.63 |
| Dr Reddys Laboratories | 95,152 | 30.15 | 35,059 | 3.90% | 4,158 | 39.81 |
| Aurobindo Pharma | 94,535 | 25.82 | 34,145 | 5.56% | 3,503 | 49.75 |
| Lupin | 93,504 | 16.93 | 29,039 | 26.75% | 5,356 | 22.87 |
| Mankind Pharma | 92,759 | 45.72 | 14,636 | 14.85% | 1,938 | 34.16 |
GlaxoSmithKline Pharmaceuticals Company Announcements - News Screener
Screen GLAXO latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-09-18 | Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot | - |
| 2026-09-18 | Shareholder Meeting / Postal Ballot-Scrutinizer"s Report | - |
| 2026-09-02 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-09-01 | Corrigendum To The Notice Of Postal Ballot Dated August 3 2026 | - |
| 2026-08-26 | Volume Movement Letter | - |
| 2026-08-26 | Clarification sought from GlaxoSmithKline Pharmaceuticals Ltd | - |
| 2026-08-19 | Disclosure Under Regulation 30 | - |
| 2026-08-14 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-13 | Shareholder Meeting / Postal Ballot-Notice of Postal Ballot | - |
| 2026-08-06 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-08-06 | Disclosure Under Regulation 30 | - |
| 2026-08-05 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-08-04 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-03 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-08-03 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-08-03 | Announcement under Regulation 30 (LODR)-Resignation of Director | - |
| 2026-08-03 | Announcement under Regulation 30 (LODR)-Change in Directorate | - |
| 2026-08-03 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-08-03 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-08-03 | Results For Quarter 30Th June 2026 | - |